je.st
news
Tag: alzheimers
PET scans can stage Alzheimers disease in living people
2016-03-08 17:00:04| Extremetech
For a while we thought amyloid plaques were the smoking gun in Alzheimer's disease, but new research out of Berkeley has shown us some surprising details about the spread of Alzheimer's through the brain - and used PET imaging to stage the disease in living people for the first time.
Does a 'Western diet' increase risk of Alzheimer's disease?
2016-03-06 05:02:00| Climate Ark Climate Change & Global Warming Newsfeed
ScienceDaily: Recent research has established associations between certain environmental factors, including eating a western diet and being sedentary, with an increased susceptibility to Alzheimer's disease. In fact, it is estimated that a combination of diet and inactivity contributes to as many as 25% of Alzheimer's cases. Nonetheless, little is known about the exact disease mechanisms and how or why this increasingly common middle-age lifestyle can play such a big role in subsequent cognitive function. In...
Tags: increase
western
risk
disease
PsychoGenics And The Alzheimer's Drug Discovery Foundation Announce A Risk-Sharing Partnership For Preclinical Studies
2016-02-03 03:43:39| drugdiscoveryonline Home Page
PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announce a new partnership to bring PsychoGenics' validated Alzheimer's animal models and experimental services to ADDF grantees working on preclinical Alzheimer's drug discovery programs
Tags: studies
foundation
drug
partnership
Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease
2016-01-28 14:00:26| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more
Study: Aspirin has potential to treat Alzheimer's, Parkinson's, other neurodegenerative diseases
2015-12-01 22:14:22| Biotech - Topix.net
Germany's antitrust agency said Wednesday Oct. 10, 2007, it had launched an investigation against Bayer AG for illegal price-fixing of aspirin. The agency confirmed a report in the German news magazine Stern that the Leverkusen-based company was under suspicion of having fixed prices with more than 11,000 pharmacies in Germany to artificially keep the price of the painkiller high.
Tags: study
potential
treat
diseases
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] next »